22 completed, 7 active not recruiting, 3 recruiting, 2 not yet recruiting. 35 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Completed 22, Active not recruiting 7, Recruiting 3, Not yet recruiting 2, Suspended 1 |
| Phase 2 | 5 | Not yet recruiting 2, Completed 1, Recruiting 1, Suspended 1 |
Follow merphos: new trials by email Literature Review of merphos trials Research Report on merphos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma Bone Scan, Cabozantinib S-malate, Cisplatin - High Grade Osteosarcoma, Localized Osteosarcoma | Phase 2 / Phase 3 | Suspended | National Cancer Institute (NCI) | 1122 | 2023-03-03 | 2026-10-27 |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 131 | 2021-11-12 | 2026-11-05 |
| Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 348 | 2021-01-25 | 2026-10-26 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Oncology Group | 5951 | 2019-10-31 | 2026-08-25 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-11-02 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 669 | 2014-12-17 | 2026-10-21 |
| Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Bortezomib, Cyclophosphamide, Cytarabine - Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 847 | 2014-10-04 | 2026-10-21 |
| Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention tacrolimus, methotrexate, Mycophenolate mofetil - Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Completed | Case Comprehensive Cancer Center | 101 | 2014-07-07 | 2023-09-11 |
| Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 488 | 2014-05-19 | 2026-09-21 |
| Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Dactinomycin, Leucovorin Calcium, Methotrexate - Choriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor | Phase 3 | Completed | GOG Foundation | 57 | 2012-06-18 | 2022-08-12 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Clofarabine, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | Phase 3 | Completed | National Cancer Institute (NCI) | 5949 | 2012-02-29 | 2026-06-02 |
| Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma | Phase 3 | Completed | Children's Oncology Group | 9350 | 2010-08-11 | 2026-05-28 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis - Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm | Phase 3 | Completed | Children's Oncology Group | 106 | 2009-03-09 | 2022-10-25 |
| Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin - Childhood Atypical Teratoid/Rhabdoid Tumor | Phase 3 | Completed | Children's Oncology Group | 70 | 2009-02-10 | 2024-04-23 |
| Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine - Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia | Phase 3 | Completed | Children's Oncology Group | 166 | 2008-07-21 | 2021-04-27 |
Showing 20 of 35. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Burkitt Lymphoma (9) · Leukemia, Biphenotypic, Acute (5) · Leukemia, Myeloid, Acute (4) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (4) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (3) · Down Syndrome (2) · Hydatidiform Mole (2) · Myelodysplastic Syndromes (2) · Myeloproliferative Disorders (2) · Osteosarcoma (2) · Anemia, Refractory (1) · Anemia, Refractory, with Excess of Blasts (1) · Choriocarcinoma (1) · Chromosome 5q Deletion Syndrome (1)
Children's Oncology Group (16) · National Cancer Institute (NCI) (14) · Case Comprehensive Cancer Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fred Hutchinson Cancer Center (1) · GOG Foundation (1) · Gynecologic Oncology Group (1)
United States (32) · Canada (23) · Australia (20) · New Zealand (14) · Puerto Rico (13) · Switzerland (8) · Israel (3) · Germany (2) · Ireland (2) · Austria (1) · Belgium (1) · Chile (1) · Czechia (1) · Finland (1) · France (1)
Anne L Angiolillo (2) · Alyssa T Reddy (1) · Andrea Biondi (1) · Bart Scott (1) · Bayard Powell (1) · Betty Hamilton, MD (1) · Beverly Lange (1) · Claire M Mazewski (1) · Cora Sternberg, Dr. (1) · David T Teachey (1) · Eric C Larsen (1) · Glen Lew, MD (1) · Heather J Symons (1) · Jean H Hoffman-Censits (1) · Jennifer L McNeer (1)
PMID 37890117, PMID 39121442, PMID 26590194, PMID 29284596, PMID 33242441, PMID 36603187, PMID 38446568, PMID 40315406, PMID 41671463, PMID 42085640, PMID 19304957, PMID 20056794, PMID 20413658, PMID 20705755, PMID 23678006, PMID 24497539, PMID 24970932, PMID 25421877, PMID 25498218, PMID 25862561, PMID 26124497, PMID 26265699, PMID 27569442, PMID 29812996, PMID 30138085, PMID 30626253, PMID 31401903, PMID 32001530, PMID 32414848, PMID 32460997, PMID 32496902, PMID 32552472, PMID 32589970, PMID 32730180, PMID 32813610, PMID 33411585, PMID 33496745, PMID 33651090, PMID 33843815, PMID 33844429, PMID 34302711, PMID 35246418, PMID 35271306, PMID 36815378, PMID 37257143, PMID 37352262, PMID 37556734, PMID 38107263, PMID 38295280, PMID 38457359
U10CA098543 (18), U10CA180886 (16), U10CA180820 (3), U10CA027469 (2), 2004 (1), 2005 (1), 2017 (1), K23HL084054 (1), N02CM62212 (1), P01CA018029 (1), P01CA078902 (1), P01HL036444 (1), U10CA021115 (1), U10CA031946 (1), U10CA180821 (1)